Clinical characteristics of the patientsa
| Group MM (n = 13) | Group UU (n = 18) | Group MU (n = 9) | Pb | |
|---|---|---|---|---|
| Age (yr) | 49.9 (SD, 14.3) | 51.6 (SD, 14.5) | 46.3 (SD, 11.1) | .61 |
| Sex | .52 | |||
| Female | 7 (53.8%) | 10 (55.6%) | 3 (33.3%) | |
| Male | 6 (46.2%) | 8 (44.4%) | 6 (66.7%) | |
| IDH 1 or 2 mutation | .06 | |||
| Negative | 9 (90.0%) | 14 (100.0%) | 6 (66.7%) | |
| Positive | 1 (10.0%) | 0 (0.0%) | 3 (33.3%) | |
| EGFR amplification: initial tumor | .85 | |||
| Negative | 7 (53.8%) | 10 (55.6%) | 4 (44.4%) | |
| Positive | 6 (46.2%) | 8 (44.4%) | 5 (55.6%) | |
| EGFR amplification: recurrent tumor | .81 | |||
| Negative | 8 (66.7%) | 10 (55.6%) | 5 (55.6%) | |
| Positive | 4 (33.3%) | 8 (44.4%) | 4 (44.4%) | |
| WHO grade: initial tumor | .12 | |||
| Grade III anaplastic astrocytoma | 1 (7.7%) | 0 (0.0%) | 2 (22.2%) | |
| Grade IV glioblastoma | 12 (92.3%) | 18 (100.0%) | 7 (77.8%) | |
| WHO grade: recurrent tumor | ||||
| Grade IV | 13 (100.0%) | 18 (100.0%) | 9 (100.0%) | |
| Surgical extent | .32 | |||
| Total resection | 11 (84.62%) | 11 (61.11%) | 7 (77.78%) | |
| Subtotal resection | 2 (15.4%) | 0 (0.0%) | 0 (0.0%) | |
| 1st preoperative KPS | 100.0 (90.0–100.0) | 92.5 (80.0–100.0) | 100.0 (90.0–100.0) | .41 |
| 2nd preoperative KPS | 90.0 (80.0–100.0) | 90.0 (70.0–100.0) | 100.0 (90.0–100.0) | .39 |
| Postoperative treatment after 1st operation | .42 | |||
| CCRT/TMZ | 11 (84.6%) | 17 (94.5%) | 8 (88.9%) | |
| Hypo-CCRT/TMZ | 2 (15.4%) | 0 (0.0%) | 0 (0.0%) | |
| Hypo-CCRT | 0 (0.0%) | 1 (5.6%) | 1 (11.1%) | |
| Radiation dose (Gy) | 61.0 (61.0–61.0) | 61.0 (61.0–61.0) | 61.0 (61.0–61.0) | .69 |
Note:—KPS indicates Karnofsky Performance Status.
↵a Data are number of patients, means [2 SDs] for normally distributed variables, or medians (interquartile ranges) for nonnormally distributed variables.
↵b P values were calculated using the Kruskal-Wallis test for nonparametric variables and the 1-way ANOVA for parametric variables.